On September 1, 2022 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, SEP 1, 2022, View Source [SID1234618903]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022

Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats
Presenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals

2022 Wells Fargo Healthcare Conference – September 7-9, 2022

Type: Investor meetings
Presenter: Vincent Anzalone, CFA, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals

H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

Baird 2022 Global Healthcare Conference – September 13-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

Morgan Stanley 20th Annual Global Healthcare Conference – September 12-14, 2022

Type: Fireside chat presentation
Presenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals

A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

On September 1, 2022 KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, reported that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York (Press release, KemPharm, SEP 1, 2022, View Source [SID1234618902]). In addition, management will be available for virtual one-on-one investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registered investors will be able to view the pre-recorded presentation by Dr. Mickle highlighting KemPharm’s business and recent corporate achievements, as well as anticipated milestones. The presentation can be viewed on-demand starting at 7:00 a.m. ET on September 12, 2022, and will be available under the "Events & Presentations" within the Investor Relations section of KemPharm’s website at View Source

On September 1, 2022 Affimed N.V. (Nasdaq: AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that the Company’s management will participate in the following investor conferences during the month of September 2022 (Press release, Affimed, SEP 1, 2022, View Source [SID1234618901]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Wells Fargo Healthcare Conference (September 6-9, 2022)
Date: Wednesday, September 7, 2022
Presentation Time: 3:10 p.m. Eastern Daylight Time
Webcast: View Source
Location: Boston, MA

Citi’s 17th Annual BioPharma Virtual Conference (September 6-8, 2022)
Date: Thursday, September 8, 2022
Only one-on-one meetings
Location: Boston, MA

Morgan Stanley’s 20th Annual Global Healthcare Conference (September 12-14, 2022)
Date: Tuesday, September 13, 2022
Only one-on-one meetings
Location: New York, NY

Jefferies Cell and Genetic Medicine Summit (September 29-30, 2022)
Date: Thursday, September 29, 2022
Only one-on-one meetings
Location: New York, NY

For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.

On September 1, 2022 Medigene AG ( View Source) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, reported that it will participate at the following upcoming scientific conferences (Press release, MediGene, SEP 1, 2022, View Source [SID1234618900]). Medigene’s management and/or scientists will be available for one-on-one meetings at these events.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

7th CAR-TCR Summit
19-22 September 2022
Boston, MA, USA
https://car-tcr-summit.com/

Immuno UK
29-30 September 2022
London, United Kingdom
View Source

10th Annual Immuno-Oncology Summit
12-14 October 2022
Boston, MA, USA
https://www.immuno-oncologysummit.com/

Cell UK
7-8 November 2022
London, United Kingdom
View Source

On September 1, 2022 Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, reported that its Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has reached key next milestones in the trial (Press release, Imugene, SEP 1, 2022, View Source [SID1234618899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The intratumoral (IT) cohort 1 has now cleared, which sees the opening of cohort 2 for IT administration, while in parallel intravenous (IV) cohort 1 has also opened. Multiple sites in the United States, have dosed the patients in IT cohort 1.

The Cohort Review Committee (CRC) unanimously agreed VAXINIA to be safe, with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed after CRC review of all safety and tolerability data for the first three patients dosed with the lowest dose of VAXINIA as monotherapy. At completion of the review meeting, the CRC advised Imugene to proceed with opening the second VAXINIA Phase 1 cohort at the mid-dose level.

The multicenter Phase 1 trial has commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours who have had at least two prior lines of standard of care treatment. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models¹.

Once patients in the monotherapy group have been treated with the lowest doses of VAXINIA and acceptable safety has been demonstrated, new study participants will receive it in combination with the immunotherapy pembrolizumab. This is expected to begin following cohort 2 being cleared per route of administration. Overall the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

The clinical trial is titled "A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST)." The trial is anticipated to run for approximately 24 months and is funded from existing budgets and resources.

Imugene MD & CEO, Ms Leslie Chong said: "Our VAXINIA trial has made headway since commencement in May. We expect this to continue as site activation and patient recruitment builds momentum and we look forward to updating our stakeholders as this positive progress continues throughout the year."